BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 38685033)

  • 1. CD8
    Chen Y; Yu D; Qian H; Shi Y; Tao Z
    J Transl Med; 2024 Apr; 22(1):394. PubMed ID: 38685033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-resident memory CD8
    Wang T; Shen Y; Luyten S; Yang Y; Jiang X
    Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 and CD8 T lymphocyte interplay in controlling tumor growth.
    Ostroumov D; Fekete-Drimusz N; Saborowski M; Kühnel F; Woller N
    Cell Mol Life Sci; 2018 Feb; 75(4):689-713. PubMed ID: 29032503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
    Fu C; Jiang A
    Front Immunol; 2018; 9():3059. PubMed ID: 30619378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolving Role of CD8
    Huff WX; Kwon JH; Henriquez M; Fetcko K; Dey M
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic CD8
    Iwahori K
    Adv Exp Med Biol; 2020; 1224():53-62. PubMed ID: 32036604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
    Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
    Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy.
    He QF; Xu Y; Li J; Huang ZM; Li XH; Wang X
    Brief Funct Genomics; 2019 Mar; 18(2):99-106. PubMed ID: 29554204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
    Chhabra A
    Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
    Spranger S
    Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
    Mylvaganam G; Yanez AG; Maus M; Walker BD
    Front Immunol; 2019; 10():2109. PubMed ID: 31552045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-resident CD8+ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression.
    Egilmez NK; Kilinc MO
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):399-405. PubMed ID: 20872283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating CD8
    Wang B; Zhou J; Li R; Tang D; Cao Z; Xu C; Xiao H
    Adv Mater; 2024 May; 36(21):e2311640. PubMed ID: 38341667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.
    Tietze JK; Wilkins DE; Sckisel GD; Bouchlaka MN; Alderson KL; Weiss JM; Ames E; Bruhn KW; Craft N; Wiltrout RH; Longo DL; Lanier LL; Blazar BR; Redelman D; Murphy WJ
    Blood; 2012 Mar; 119(13):3073-83. PubMed ID: 22251483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.